Skip to content

Study · Non-randomized trial · n = 9 · 1998

4 results

A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men.

Nijland EA, Strasburger CJ, Popp-Snijders C, van der Wal PS, van der Veen EA

European journal of endocrinology1 Oct 1998Cited by 9 (Europe PMC)

PMID9820615 (opens in a new tab)DOI10.1530/eje.0.1390395 (opens in a new tab)PepBankPUB-09820615
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In nine healthy young men, peak GH after daily GHRP‑2 fell from 83 on day 1 to 59 on day 3 and 51 microg/l on day 5, which shows response attenuation.

    In plain wordsIn healthy young men, the growth hormone peak after daily GHRP‑2 shots got smaller over five days.

    Peptide
    GHRP-2
    Outcome
    DecreasePeak GH concentration over 5 days of treatment
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg · subcutaneous · 5 daysAs given in this study (human).

    Measurements

    peak GH
    83 microg/l
    day 1
    peak GH
    59 microg/l
    day 3
    peak GH
    51 microg/l
    day 5

    Source sentences

    Summary
    Mean-/+S.D). peak GH concentrations were 83+/-31, 59+/-22 and 51+/-13 microg/l on days 1, 3 and 5 respectively.
    2 context sentences
    Summary · context
    Despite the maintained GH release, analysis of variance revealed that significant response attenuation occurred (P < 0.01).
    Summary · context
    To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In nine healthy young men, the GH area under the curve after daily GHRP‑2 fell from 6366 on day 1 to 3987 on day 3 and 3392 mU/l per min on day 5, with significant response attenuation.

    In plain wordsIn healthy young men, total growth hormone release after each daily GHRP‑2 shot fell over five days.

    Peptide
    GHRP-2
    Outcome
    DecreaseGH area under the curve over 5 days of treatment
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg · subcutaneous · 5 daysAs given in this study (human).

    Measurements

    GH AUC
    6366 mU/l per min
    day 1
    GH AUC
    3987 mU/l per min
    day 3
    GH AUC
    3392 mU/l per min
    day 5

    Source sentences

    Summary
    Mean+/-S.D. areas under the curve for days 1, 3 and 5 were 6366+/-2514, 3987 +/- 1418 and 3392+/-1215 mU/l per min.
    2 context sentences
    Summary · context
    Despite the maintained GH release, analysis of variance revealed that significant response attenuation occurred (P < 0.01).
    Summary · context
    To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days.
  3. 03HumanNon-randomized trialEfficacy outcome

    In nine healthy young men, mean serum IGF-I did not increase after 5 days of GHRP‑2 treatment.

    In plain wordsIn healthy young men, five days of daily GHRP‑2 did not raise IGF-I in the blood.

    Peptide
    GHRP-2
    Outcome
    No significant changeSerum IGF-I
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg · subcutaneous · 5 daysAs given in this study (human).

    Source sentences

    Summary
    Mean serum IGF-I concentration did not increase after a 5 day treatment with GHRP-2.
    1 context sentence
    Summary · context
    To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days.
  4. 04HumanNon-randomized trialEfficacy outcome

    In nine healthy young men, serum osteocalcin increased significantly from 3.2 to 4.2 microg/l after 5 days of GHRP‑2.

    In plain wordsIn healthy young men, five days of daily GHRP‑2 raised osteocalcin, a blood marker of growth hormone action in tissue.

    Peptide
    GHRP-2
    Outcome
    IncreaseSerum osteocalcin
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg · subcutaneous · 5 daysAs given in this study (human).

    Measurements

    osteocalcin
    3.2 microg/l
    baseline
    osteocalcin
    4.2 microg/l
    after treatment

    Source sentences

    Summary
    However, osteocalcin, another serum marker of GH activity in tissue, increased significantly from 3.2+/-1.0 to 4.2+/-0.4 microg/l (mean+S.D.) (P< 0.01).
    1 context sentence
    Summary · context
    To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.